

# Michael Weller

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3232536/michael-weller-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

758  
papers

74,217  
citations

114  
h-index

259  
g-index

824  
ext. papers

89,553  
ext. citations

6.5  
avg, IF

7.66  
L-index

| #   | Paper   | IF  | Citations |
|-----|---|-----|-----------|
| 758 | Die WHO-Klassifikation der Tumoren des zentralen Nervensystems 2021. <i>Onkologe</i> , <b>2022</b> , 28, 155-163  | 0.1 |           |
| 757 | Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. <i>Hematology/Oncology Clinics of North America</i> , <b>2022</b> , 36, 113-132  | 3.1 | 1         |
| 756 | A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.. <i>EMBO Molecular Medicine</i> , <b>2022</b> , e14552                                  | 12  | 2         |
| 755 | Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.. <i>Cancers</i> , <b>2022</b> , 14,   | 6.6 | 2         |
| 754 | DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.. <i>Acta Neuropathologica Communications</i> , <b>2022</b> , 10, 39                      | 7.3 | 1         |
| 753 | Opportunities and Challenges for the development of 'Core Outcome Sets' in Neuro-Oncology.. <i>Neuro-Oncology</i> , <b>2022</b> ,   | 1   | 1         |
| 752 | Prognosis of walking function in multiple sclerosis supported by gait pattern analysis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 63, 103802   | 4   |           |
| 751 | Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.. <i>Neuro-Oncology</i> , <b>2022</b> ,                                | 1   | 6         |
| 750 | Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.. <i>Neuro-Oncology</i> , <b>2022</b> ,   | 1   | 8         |
| 749 | Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings.. <i>BMJ Open</i> , <b>2022</b> , 12, e057384 | 3   | 0         |
| 748 | CSIG-17. IMMUNE MODULATORY ROLE OF TYPE I INTERFERON IN SYNGENEIC MOUSE GLIOMA MODELS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi36-vi37  | 1   |           |
| 747 | NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi126-vi127                               | 1   | 0         |
| 746 | DDRE-21. LOMUSTINE AND TARGETED-CYTOKINE THERAPY: A BENEFICIAL LIAISON FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi78-vi79  | 1   |           |
| 745 | EPCO-09. LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi3-vi3                              | 1   |           |
| 744 | IMMU-13. COMBINED MODULATION OF THE TGF- $\beta$ PATHWAY AND GITR IMMUNE CHECKPOINT SIGNALING PROMOTES ANTI-TUMOR IMMUNITY IN SYNGENEIC GLIOMA MODELS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi94-vi94                              | 1   |           |
| 743 | IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi101-vi101  | 1   |           |
| 742 | EXTH-21. MECHANISMS OF SYNERGISTIC GROWTH SUPPRESSION BY RADIOTHERAPY AND C-MET INHIBITION IN EXPERIMENTAL GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi167-vi168  | 1   |           |

|     |  |      |    |
|-----|--|------|----|
| 741 | CSIG-22. Cd95L/Cd95 GENE DELETION DECREASES MOUSE GLIOMA TUMORIGENESIS THROUGH THE INHIBITION OF NON-CANONICAL CD95L/CD95-MEDIATED CELL GROWTH AND IMMUNOSUPPRESSION. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi37-vi38  | 1    |    |
| 740 | PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi123-vi124   | 1    |    |
| 739 | CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi55-vi56                                   | 1    | 3  |
| 738 | Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials. <i>Clinical Cancer Research</i> , <b>2021</b> ,   | 12.9 | 2  |
| 737 | Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , <b>2021</b> , 3, e784-e794  | 14.4 | 6  |
| 736 | Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3839-3852   | 2.2  | 8  |
| 735 | Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , <b>2021</b> ,   | 1    | 1  |
| 734 | Gliome des Erwachsenenalters. <i>Springer Reference Medizin</i> , <b>2021</b> , 1-12   | 0    |    |
| 733 | Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1100-1112  | 1    | 17 |
| 732 | Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 945-957   | 14.3 | 9  |
| 731 | Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 298   | 4    | 9  |
| 730 | A tumor-promoting role for soluble TRIM3 in glioblastoma. <i>Molecular and Cellular Biochemistry</i> , <b>2021</b> , 476, 2963-2973  | 4.2  | 0  |
| 729 | Chemotherapy for adult patients with spinal cord gliomas. <i>Neuro-Oncology Practice</i> , <b>2021</b> , 8, 475-484  | 2.2  |    |
| 728 | Pathway-based stratification of glioblastoma. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 263-264  | 15   | 0  |
| 727 | Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. <i>Molecular Therapy - Oncolytics</i> , <b>2021</b> , 20, 166-174  | 6.4  | 1  |
| 726 | Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 636672   | 5.3  | 1  |
| 725 | Distinct Cerebrovascular Reactivity Patterns for Brain Radiation Necrosis. <i>Cancers</i> , <b>2021</b> , 13,  | 6.6  | 2  |
| 724 | Telomerase reverse transcriptase promoter mutation- and O-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 84-94 | 7.5  | 3  |

|     |   |      |    |
|-----|---|------|----|
| 723 | Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression. <i>ACS Central Science</i> , <b>2021</b> , 7, 868-881   | 16.8 | 7  |
| 722 | HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy <b>2021</b> , 9,  |      | 26 |
| 721 | Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1547-1559   | 1    | 7  |
| 720 | Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 1-12                             | 7.5  | 2  |
| 719 | Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1208-1209  | 1    |    |
| 718 | Digital measurement of functional status of patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2016-2016  | 2.2  |    |
| 717 | EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2004-2004 | 2.2  | 5  |
| 716 | PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. <i>Journal of Neuro-Oncology</i> , <b>2021</b> , 153, 283-291   | 4.8  | 1  |
| 715 | GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS2074-TPS2074  | 2.2  | 1  |
| 714 | Cancer is associated with inferior outcome in patients with ischemic stroke. <i>Journal of Neurology</i> , <b>2021</b> , 268, 4190-4202   | 5.5  | 0  |
| 713 | Evidence-based recommendations on categories for extent of resection in diffuse glioma. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 23-33  | 7.5  | 17 |
| 712 | Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma.. <i>Med</i> , <b>2021</b> , 2, 450-457   | 4.5  | 1  |
| 711 | Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). <i>Swiss Medical Weekly</i> , <b>2021</b> , 151, w20501  | 3.1  | 0  |
| 710 | Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1612-1613   | 1    |    |
| 709 | Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 97, 102189  | 14.4 | 10 |
| 708 | SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1835-1844   | 1    | 13 |
| 707 | Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. <i>Cancers</i> , <b>2021</b> , 13,   | 6.6  | 2  |
| 706 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 813-823                                   | 21.7 | 24 |

|     |   |      |     |
|-----|---|------|-----|
| 705 | Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , <b>2021</b> , 13,  | 6.6  | 2   |
| 704 | CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 457-467  | 1    | 18  |
| 703 | MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 179-188     | 12.9 | 5   |
| 702 | The molecular evolution of glioblastoma treated by gross total resection alone. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 334-336   | 1    | 1   |
| 701 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 170-186   | 19.4 | 204 |
| 700 | Treatment Monitoring of Immunotherapy and Targeted Therapy Using F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 464-470                            | 8.9  | 10  |
| 699 | Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, vdab048                               | 0.9  | 2   |
| 698 | Kindliche Hirntumoren bei Erwachsenen: Medulloblastom. <i>Springer Reference Medizin</i> , <b>2021</b> , 1-8  | 0    |     |
| 697 | Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 506-507   | 1    |     |
| 696 | Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF- $\beta$ and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, vdab058                   | 0.9  | 5   |
| 695 | A vasculature-centric approach to developing novel treatment options for glioblastoma. <i>Expert Opinion on Therapeutic Targets</i> , <b>2021</b> , 25, 87-100  | 6.4  | 4   |
| 694 | Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , <b>2021</b> , 8, 417-425 | 2.2  | 0   |
| 693 | Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 881-893  | 1    | 23  |
| 692 | Radiotherapy for glioblastoma patients with poor performance status. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 1  | 4.9  | 0   |
| 691 | SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, iii25-iii25   | 0.9  | 78  |
| 690 | BSCI-02. METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, iii1-iii1  | 0.9  | 78  |
| 689 | SYST-03. A PHASE I/II STUDY TO EVALUATE SAFETY AND PRELIMINARY ACTIVITY OF THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF IN PATIENTS WITH GLIOBLASTOMA AT FIRST RELAPSE. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, iv8-iv9      | 0.9  |     |
| 688 | The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 885   | 9.8  | 2   |

|     |   |      |     |
|-----|---|------|-----|
| 687 | Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , <b>2021</b> ,  | 12.9 | 4   |
| 686 | Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , <b>2021</b> ,  | 12.9 | 4   |
| 685 | The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , <b>2021</b> , 156, 93-108  | 7.5  | 5   |
| 684 | Economic Impact of Poststroke Delirium and Associated Risk Factors: Findings From a Prospective Cohort Study. <i>Stroke</i> , <b>2021</b> , 52, 3325-3334   | 6.7  | 0   |
| 683 | EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1821-1834  |      | 32  |
| 682 | Endoglin and TGF- $\beta$ signaling in glioblastoma. <i>Cell and Tissue Research</i> , <b>2021</b> , 384, 613-624   | 4.2  | 2   |
| 681 | mA Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 760892  | 5.3  | 0   |
| 680 | Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , <b>2021</b> , 35, 29     | 2.8  | 1   |
| 679 | Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?. <i>Current Opinion in Neurology</i> , <b>2020</b> , 33, 701-706 | 7.1  | 6   |
| 678 | Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors. <i>MAbs</i> , <b>2020</b> , 12, 1836713   | 6.6  | 0   |
| 677 | Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. <i>Journal of Neuro-Oncology</i> , <b>2020</b> , 148, 117-130                                | 4.8  | 6   |
| 676 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1003-1010  | 13.4 | 328 |
| 675 | Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR Phosphorylation. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 1328-1339                                      | 6.1  | 6   |
| 674 | How did lomustine become standard of care in recurrent glioblastoma?. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 87, 102029  | 14.4 | 40  |
| 673 | Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1667-1676                              | 1    | 4   |
| 672 | Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , <b>2020</b> , 134, 75-85   | 7.5  | 3   |
| 671 | Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invasive Leukocytes. <i>Cell</i> , <b>2020</b> , 181, 1626-1642.e20  | 56.2 | 154 |
| 670 | PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5287-5296   | 12.9 | 48  |

|     |   |      |      |
|-----|---|------|------|
| 669 | Impaired speed-dependent modulation of the gait pattern in multiple sclerosis. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2998-3007   | 5.5  | 1    |
| 668 | Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1262-1275   | 1    | 38   |
| 667 | Socioeconomic burden and quality of life in meningioma patients. <i>Quality of Life Research</i> , <b>2020</b> , 29, 1803-1808  | 3.7  | 1805 |
| 666 | Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1568-1579   | 1    | 15   |
| 665 | Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 150-158   | 7.5  | 4    |
| 664 | CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , <b>2020</b> , 140, 409-413  | 14.3 | 26   |
| 663 | Interferon- $\beta$ exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdaa043  | 0.9  |      |
| 662 | Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 757-772  | 1    | 45   |
| 661 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1162-1172   | 1    | 22   |
| 660 | Burnout and career satisfaction in neuro-oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology memberships. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 838-850   | 1    | 3    |
| 659 | Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. <i>Neuro-Oncology Practice</i> , <b>2020</b> , 7, 249-259  | 2.2  |      |
| 658 | cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , <b>2020</b> , 139, 603-608   | 14.3 | 170  |
| 657 | Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, e97-e103  | 21.7 | 19   |
| 656 | End-of-life care for glioma patients; the caregivers' perspective. <i>Journal of Neuro-Oncology</i> , <b>2020</b> , 147, 663-669  | 4.8  | 3    |
| 655 | Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. <i>Cancer Letters</i> , <b>2020</b> , 480, 24-28  | 9.9  | 21   |
| 654 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1073-1113  | 1    | 178  |
| 653 | Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2521-2521 | 2.2  | 1    |
| 652 | The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3128-3128   | 2.2  | 1    |

|     |   |      |    |
|-----|---|------|----|
| 651 | GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS2579-TPS2579             | 2.2  | 3  |
| 650 | Interferon- $\beta$ sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Oncology Letters</i> , <b>2020</b> , 19, 2649-2656   | 2.6  | 2  |
| 649 | A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. <i>Swiss Medical Weekly</i> , <b>2020</b> , 150, w20256   | 3.1  | 3  |
| 648 | Treatment of Leptomeningeal Metastases <b>2020</b> , 301-311  |      |    |
| 647 | CNS Tumors in Older Adults <b>2020</b> , 813-821  |      |    |
| 646 | Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e14530-e14530   | 2.2  |    |
| 645 | Single cell mapping of human brain tumors reveals tumor-specific education of tissue-invading leukocytes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2509-2509  | 2.2  | 0  |
| 644 | Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours. <i>ESMO Open</i> , <b>2020</b> , 5, e001034  | 6    | 3  |
| 643 | Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdaa147              | 0.9  | 1  |
| 642 | Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 601-612                                      | 1    | 12 |
| 641 | Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 524-538               | 1    | 25 |
| 640 | Predisposing and precipitating risk factors for delirium in palliative care patients. <i>Palliative and Supportive Care</i> , <b>2020</b> , 18, 437-446   | 2.5  | 11 |
| 639 | Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. <i>Journal of Neurochemistry</i> , <b>2020</b> , 153, 510-524 | 6    | 3  |
| 638 | YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , <b>2020</b> , 139, 215-218  | 14.3 | 24 |
| 637 | Does Neuronal Activity Promote Glioma Progression?. <i>Trends in Cancer</i> , <b>2020</b> , 6, 1-3  | 12.5 | 6  |
| 636 | Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis. <i>European Journal of Cancer</i> , <b>2020</b> , 124, 194-203      | 7.5  | 10 |
| 635 | Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 659-670  | 4.9  | 10 |
| 634 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 684-693         | 1    | 62 |



|     |   |      |    |
|-----|---|------|----|
| 633 | 32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii5-ii6  | 0.9  | 1  |
| 632 | Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. <i>Neuro-Oncology Practice</i> , <b>2020</b> , 7, 668-675   | 2.2  | 2  |
| 631 | Immunocytokines are a promising immunotherapeutic approach against glioblastoma. <i>Science Translational Medicine</i> , <b>2020</b> , 12,  | 17.5 | 26 |
| 630 | Neutrophils Obstructing Brain Capillaries Are a Major Cause of No-Reflow in Ischemic Stroke. <i>Cell Reports</i> , <b>2020</b> , 33, 108260   | 10.6 | 33 |
| 629 | Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8373-8385  | 4.8  | 7  |
| 628 | An engineered 4-1BBL fusion protein with "activity on demand". <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 31780-31788  | 11.5 | 8  |
| 627 | Appropriate Analysis of Duration of Response Data in Cancer Trials-Reply. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1978-1979   | 11.5 | 8  |
| 626 | Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 1133-1141   | 5.9  | 17 |
| 625 | Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , <b>2020</b> , 297, 164-175 | 20.5 | 7  |
| 624 | Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>ESMO Open</i> , <b>2020</b> , 5,   | 6    | 7  |
| 623 | Crossed Cerebellar Diaschisis in Patients with Diffuse Glioma Is Associated with Impaired Supratentorial Cerebrovascular Reactivity and Worse Clinical Outcome. <i>Cerebellum</i> , <b>2020</b> , 19, 824-832   | 4.3  | 6  |
| 622 | Prognostic value of O-(2-[F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. <i>Acta Oncologica</i> , <b>2020</b> , 59, 1357-1364   | 3.2  |    |
| 621 | Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , <b>2020</b> , 7, 599-612   | 2.2  | 9  |
| 620 | 42. IDENTIFICATION OF BRAIN METASTASIS VULNERABILITIES USING METPLATFORM. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii8-ii8   | 0.9  | 78 |
| 619 | Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Translational Oncology</i> , <b>2020</b> , 13, 100852  | 4.9  | 1  |
| 618 | Response to Letter to Editor. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1706-1707   | 1    | 1  |
| 617 | Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1742-1756   | 1    | 7  |
| 616 | Antidepressant drug use in glioblastoma patients: an epidemiological view. <i>Neuro-Oncology Practice</i> , <b>2020</b> , 7, 514-521  | 2.2  | 2  |

|     |  |      |     |
|-----|--|------|-----|
| 615 | DEPOSEIN-how meaningful was the benefit from intrathecal chemotherapy?. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1710-1711  | 1    |     |
| 614 | Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. <i>Nature Communications</i> , <b>2020</b> , 11, 6434   | 17.4 | 7   |
| 613 | How we treat patients with brain tumour during the COVID-19 pandemic. <i>ESMO Open</i> , <b>2020</b> , 4, e000789  | 6    | 7   |
| 612 | Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 803-809   | 7.5  | 20  |
| 611 | Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 17-30  | 1    | 43  |
| 610 | Risk factors for the development of epilepsy in patients with brain metastases. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 718-728  | 1    | 8   |
| 609 | FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. <i>Acta Neuropathologica</i> , <b>2020</b> , 139, 175-192  | 14.3 | 4   |
| 608 | EANO guideline on the diagnosis and treatment of vestibular schwannoma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 31-45  | 1    | 66  |
| 607 | Hemodynamic investigation of peritumoral impaired blood oxygenation-level dependent cerebrovascular reactivity in patients with diffuse glioma. <i>Magnetic Resonance Imaging</i> , <b>2020</b> , 70, 50-56  | 3.3  | 4   |
| 606 | cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , <b>2020</b> , 30, 844-856  | 6    | 196 |
| 605 | Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , <b>2019</b> , 7, 163   | 7.3  | 18  |
| 604 | Predisposing and precipitating factors for delirium in neurology: a prospective cohort study of 1487 patients. <i>Journal of Neurology</i> , <b>2019</b> , 266, 3065-3075  | 5.5  | 13  |
| 603 | Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 145, 339-347  | 4.8  | 2   |
| 602 | Anticonvulsive effect of anterior thalamic deep brain stimulation in super-refractory status epilepticus crucially depends on active stimulation zone-A single case observation. <i>Seizure: the Journal of the British Epilepsy Association</i> , <b>2019</b> , 71, 286-288                         | 3.2  | 8   |
| 601 | Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. <i>Neurology</i> , <b>2019</b> , 93, e1799-e1806  | 6.5  | 5   |
| 600 | Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 571-584   | 1    | 67  |
| 599 | The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 648-658  | 1    | 50  |
| 598 | The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , <b>2019</b> , 116, 190-198 | 7.5  | 11  |

|     |   |      |    |
|-----|---|------|----|
| 597 | DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 901-910                       | 1    | 79 |
| 596 | Concepts of Personalized Medicine in Neuro-oncology <b>2019</b> , 153-158   |      |    |
| 595 | Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1263-1272  | 1    | 12 |
| 594 | Glioblastoma <b>2019</b> , 237-247  |      |    |
| 593 | Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , <b>2019</b> , 138, 295-308  | 14.3 | 27 |
| 592 | Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. <i>EMBO Molecular Medicine</i> , <b>2019</b> , 11,  | 12   | 21 |
| 591 | Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , <b>2019</b> , 92, e2754-e2763  | 6.5  | 6  |
| 590 | CHD7 promotes glioblastoma cell motility and invasiveness through transcriptional modulation of an invasion signature. <i>Scientific Reports</i> , <b>2019</b> , 9, 3952  | 4.9  | 9  |
| 589 | Evolutionary Trajectories of IDH Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. <i>Cancer Cell</i> , <b>2019</b> , 35, 692-704.e12                            | 24.3 | 92 |
| 588 | Immunotherapy for glioblastoma: quo vadis?. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 405-406   | 19.4 | 12 |
| 587 | Basics of Brain Tumor Biology for Clinicians <b>2019</b> , 7-19   |      |    |
| 586 | Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 234-241  | 1    | 8  |
| 585 | In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study. <i>Journal of Sleep Research</i> , <b>2019</b> , 28, e12721   | 5.8  | 3  |
| 584 | Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 26-36                       | 1    | 54 |
| 583 | Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1607-1609                                      | 1    | 6  |
| 582 | Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1587-1594 | 1    | 26 |
| 581 | How we treat glioblastoma. <i>ESMO Open</i> , <b>2019</b> , 4, e000520  | 6    | 39 |
| 580 | Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1447-1457              | 1    | 19 |

|     |   |      |     |
|-----|---|------|-----|
| 579 | Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1100-1117   | 1    | 25  |
| 578 | Complementary and alternative medicine use in glioma patients in France. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 145, 487-499  | 4.8  | 7   |
| 577 | Lymphatic outflow of cerebrospinal fluid is reduced in glioma. <i>Scientific Reports</i> , <b>2019</b> , 9, 14815   | 4.9  | 27  |
| 576 | MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA. <i>Neuro-Oncology Advances</i> , <b>2019</b> , 1, i17-i17   | 0.9  | 78  |
| 575 | Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 80, 101896  | 14.4 | 167 |
| 574 | High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. <i>Molecular Oncology</i> , <b>2019</b> , 13, 2305-2328   | 7.9  | 43  |
| 573 | Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. <i>JCI Insight</i> , <b>2019</b> , 4,  | 9.9  | 18  |
| 572 | Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2000-2000                                    | 2.2  | 28  |
| 571 | Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2007-2007   | 2.2  | 12  |
| 570 | Barriers to accrual and enrollment in brain tumor trials.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2024-2024  | 2.2  | 1   |
| 569 | Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2056-2056   | 2.2  | 1   |
| 568 | EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2060-2060 | 2.2  | 5   |
| 567 | Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2013-2013  | 2.2  |     |
| 566 | Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 678-688                                | 4.0  | 207 |
| 565 | How we treat patients with leptomeningeal metastases. <i>ESMO Open</i> , <b>2019</b> , 4, e000507   | 6    | 37  |
| 564 | CSIG-06. DEPATUXIZUMAB MAFODOTIN (ABT-414)-INDUCED GLIOBLASTOMA CELL DEATH REQUIRES EGFR OVEREXPRESSION, BUT NOT PHOSPHORYLATION. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi45-vi45 <sup>1</sup>  |      | 78  |
| 563 | EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi76-vi76  | 1    | 78  |
| 562 | INN-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi137-vi137   | 1    | 10  |

|     |  |      |     |
|-----|--|------|-----|
| 561 | DDIS-04. INTERFERON- $\beta$ SENSITIZES HUMAN GLIOBLASTOMA CELLS TO THE CYCLIN-DEPENDENT KINASE INHIBITOR, TG02. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi65-vi66   | 1    | 78  |
| 560 | CBMT-12. FOCAD LOSS IMPACTS MICROTUBULE ASSEMBLY, G2/M PROGRESSION AND PATIENT SURVIVAL IN ASTROCYTIC GLIOMAS. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi35-vi35   | 1    | 78  |
| 559 | QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi197-vi198   | 1    | 0   |
| 558 | ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi21-vi22                | 1    | 6   |
| 557 | IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi122-vi122   | 1    | 78  |
| 556 | ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi12-vi12  | 1    | 3   |
| 555 | ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi14-vi14               | 1    | 4   |
| 554 | IMMU-08. THE ANTIGENIC LANDSCAPE OF GLIOBLASTOMA - REFINING THE TARGETS FOR IMMUNOTHERAPY. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi120-vi120   | 1    | 78  |
| 553 | EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e715-e728   | 21.7 | 31  |
| 552 | LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi285-vi285   | 1    | 0   |
| 551 | Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , <b>2019</b> , 576, 112-120  | 50.4 | 151 |
| 550 | QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi198-vi198 | 1    | 78  |
| 549 | Therapeutic Targeting of TGF $\beta$ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7189-7201  | 12.9 | 22  |
| 548 | Complementary and alternative medicine use by glioma patients in Switzerland. <i>Neuro-Oncology Practice</i> , <b>2019</b> , 6, 237-244  | 2.2  | 7   |
| 547 | Management of low-grade glioma: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , <b>2019</b> , 6, 249-258   | 2.2  | 24  |
| 546 | PET imaging in patients with brain metastasis-report of the RANO/PET group. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 585-595  | 1    | 72  |
| 545 | Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. <i>Journal of Controlled Release</i> , <b>2019</b> , 295, 130-139   | 11.7 | 36  |
| 544 | Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 242-253  | 7.5  | 15  |

|     |   |      |     |
|-----|---|------|-----|
| 543 | Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 540-557 | 8.8  | 198 |
| 542 | Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1809-1816                            | 12.9 | 159 |
| 541 | Contraceptive drugs mitigate experimental stroke-induced brain injury. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 637-646  | 9.9  | 9   |
| 540 | MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy. <i>Neuropathology and Applied Neurobiology</i> , <b>2019</b> , 45, 441-458                             | 5.2  | 15  |
| 539 | Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2018</b> , 365, 422-429   | 4.7  | 5   |
| 538 | Transcriptional control of O -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. <i>Journal of Neurochemistry</i> , <b>2018</b> , 144, 780-790   | 6    | 15  |
| 537 | Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e173-e180  | 21.7 | 23  |
| 536 | Diagnostic value of F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , <b>2018</b> , 96, 64-72  | 7.5  | 14  |
| 535 | Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 153-166  | 14.3 | 162 |
| 534 | Next generation neuro-oncology. <i>European Journal of Cancer</i> , <b>2018</b> , 96, 1-5   | 7.5  | 5   |
| 533 | Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 955-963  | 14.3 | 61  |
| 532 | Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 422-442  | 19.4 | 466 |
| 531 | Where does O -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?. <i>Cancer</i> , <b>2018</b> , 124, 1316-1318  | 6.4  | 8   |
| 530 | Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 138, 163-171   | 4.8  | 24  |
| 529 | EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 445-456  |      | 100 |
| 528 | DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , <b>2018</b> , 555, 469-474  | 50.4 | 992 |
| 527 | The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 923-938  | 14.3 | 18  |
| 526 | Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 273-291   | 14.3 | 99  |

|     |  |      |     |
|-----|--|------|-----|
| 525 | Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time. <i>Scientific Reports</i> , <b>2018</b> , 8, 4984   | 4.9  | 58  |
| 524 | Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). <i>Neuro-Oncology</i> , <b>2018</b> , 20, 400-410   | 1    | 36  |
| 523 | Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 279-288  | 1    | 52  |
| 522 | Diffuse gliomas exhibit whole brain impaired cerebrovascular reactivity. <i>Magnetic Resonance Imaging</i> , <b>2018</b> , 45, 78-83   | 3.3  | 16  |
| 521 | Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 367-379   | 1    | 35  |
| 520 | Copy number profiling across glioblastoma populations has implications for clinical trial design. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 1368-1373  | 1    | 18  |
| 519 | Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. <i>Journal of Neurochemistry</i> , <b>2018</b> , 147, 99-109   | 6    | 13  |
| 518 | DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 1616-1624  | 1    | 32  |
| 517 | Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , <b>2018</b> , 101, 95-104  | 7.5  | 7   |
| 516 | Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. <i>Cancer Cell</i> , <b>2018</b> , 34, 163-177.e7  | 24.3 | 79  |
| 515 | Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , <b>2018</b> , 24, 1192-1203  | 50.5 | 174 |
| 514 | Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. <i>Journal of Neurosurgery</i> , <b>2018</b> , 129, 1104-1105   | 3.2  | 1   |
| 513 | Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 1170-1179   | 21.7 | 49  |
| 512 | TGF- $\beta$ induces oncofetal fibronectin that, in turn, modulates TGF- $\beta$ superfamily signaling in endothelial cells. <i>Journal of Cell Science</i> , <b>2018</b> , 131,   | 5.3  | 20  |
| 511 | Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2023-2023 | 2.2  | 10  |
| 510 | CNS Tumors in Older Adults <b>2018</b> , 1-9   |      |     |
| 509 | Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2013-2013  | 2.2  |     |
| 508 | Sensitization of glioblastoma to alkylating chemotherapy by ultrasound-mediated delivery of therapeutic liposomes.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14061-e14061  | 2.2  |     |

|     |   |      |     |
|-----|---|------|-----|
| 507 | Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2042-2042  | 2.2  |     |
| 506 | Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14070-e14070  | 2.2  |     |
| 505 | Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14062-e14062  | 2.2  |     |
| 504 | A tissue-based draft map of the murine MHC class I immunopeptidome. <i>Scientific Data</i> , <b>2018</b> , 5, 180157  | 8.2  | 23  |
| 503 | NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 882-895  | 12.9 | 37  |
| 502 | NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. <i>Cancer Research</i> , <b>2018</b> , 78, 1031-1043   | 10.1 | 117 |
| 501 | Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. <i>International Journal of Pharmaceutics</i> , <b>2018</b> , 536, 388-396  | 6.5  | 7   |
| 500 | ACTR-53. STEAM / EORTC 1608: STUDY OF TG02 IN ELDERLY NEWLY DIAGNOSED OR ADULT RELAPSED PATIENTS WITH ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA - A PHASE 1B STUDY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi23-vi24  | 1    | 78  |
| 499 | RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi235-vi236 | 1    | 78  |
| 498 | PATH-51. DNA COPY NUMBER PROFILING ACROSS GLIOBLASTOMA POPULATIONS HAS IMPLICATIONS FOR CLINICAL TRIAL DESIGN. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi169-vi170  | 1    | 78  |
| 497 | IMMU-53. IMPACT OF TUMOR-TREATING FIELDS (TTFIELDS) ON THE IMMUNOGENICITY OF GLIOMA CELLS. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi133-vi133  | 1    | 1   |
| 496 | RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi240-vi240  | 1    | 1   |
| 495 | ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi4-vi4   | 1    | 2   |
| 494 | QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi221-vi221 <sup>1</sup>  |      | 78  |
| 493 | ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi22-vi22                             | 1    | 78  |
| 492 | CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi48-vi49   | 1    | 78  |
| 491 | CSIG-26. MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi48-vi48   | 1    | 78  |
| 490 | CMET-39. INTRA-CSF LIPOSOMAL CYTARABINE PLUS SYSTEMIC THERAPY AS INITIAL TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS: A RANDOMISED, OPEN-LABEL TRIAL. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi61-vi62  | 1    | 1   |



|     |  |      |     |
|-----|--|------|-----|
| 489 | ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi25-vi25  | 1    | 78  |
| 488 | ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIO THERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi114-vi114                | 1    | 78  |
| 487 | CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi59-vi59   | 1    | 78  |
| 486 | MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi151-vi151  | 1    | 78  |
| 485 | MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi148-vi149   | 1    | 78  |
| 484 | QOLP-27. USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN GLIOMA PATIENTS. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi220-vi220   | 1    | 78  |
| 483 | Pseudoprogession: fact or wishful thinking in neuro-oncology?. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1561-1567   | 13   | 13  |
| 482 | ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX <sup>®</sup> ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406). <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi20-vi20 | 1    | 1   |
| 481 | Hyper-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2744-2753  | 2.2  | 18  |
| 480 | cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 805-810  | 14.3 | 367 |
| 479 | Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 975-978   | 14.3 | 5   |
| 478 | Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 793-803                             | 14.3 | 102 |
| 477 | Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 140, 659-667  | 4.8  | 7   |
| 476 | Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 897-906   | 1    | 26  |
| 475 | Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets?. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 68, 145-154  | 14.4 | 43  |
| 474 | Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 1255-1262  | 1    | 15  |
| 473 | Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. <i>Neurology</i> , <b>2017</b> , 88, 832-841  | 6.5  | 26  |
| 472 | Glioblastoma <b>2017</b> , 265-288   |      | 1   |

|     |  |      |     |
|-----|--|------|-----|
| 471 | Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , <b>2017</b> , 19, 162-174  | 1    | 244 |
| 470 | Biological activity of tumor-treating fields in preclinical glioma models. <i>Cell Death and Disease</i> , <b>2017</b> , 8, e2753  | 9.8  | 53  |
| 469 | Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 1815-1821                           | 4.9  | 38  |
| 468 | Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , <b>2017</b> , 13, 363-374  | 15   | 82  |
| 467 | Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 1338-1349   | 1    | 28  |
| 466 | Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF- $\beta$ and Furin in Glioma-Initiating Cells. <i>Journal of Immunology</i> , <b>2017</b> , 198, 4569-4574   | 5.3  | 14  |
| 465 | European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e315-e329  | 21.7 | 599 |
| 464 | Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 133, 419-427  | 4.8  | 38  |
| 463 | Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. <i>Acta Neuropathologica Communications</i> , <b>2017</b> , 5, 39 | 7.3  | 65  |
| 462 | PET imaging in patients with meningioma-report of the RANO/PET Group. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 1576-1587  | 1    | 97  |
| 461 | A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 614-624   | 1    | 79  |
| 460 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 1119-1126   | 1    | 82  |
| 459 | Management of Elderly Patients with Glioblastoma. <i>Current Neurology and Neuroscience Reports</i> , <b>2017</b> , 17, 35   | 6.6  | 5   |
| 458 | Biological Role and Therapeutic Targeting of TGF- $\beta$ in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1177-1186  | 6.1  | 37  |
| 457 | Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. <i>Neurology</i> , <b>2017</b> , 88, 1422-1430  | 6.5  | 35  |
| 456 | DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 682-694   | 21.7 | 336 |
| 455 | The network of immunosuppressive pathways in glioblastoma. <i>Biochemical Pharmacology</i> , <b>2017</b> , 130, 1-9  | 6    | 56  |
| 454 | Advances in the molecular genetics of gliomas - implications for classification and therapy. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 434-452   | 19.4 | 320 |

|     |  |      |     |
|-----|--|------|-----|
| 453 | Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-Methylguanine-DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 343-351 | 2.2  | 77  |
| 452 | Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models. <i>Journal of Neurochemistry</i> , <b>2017</b> , 140, 170-182  | 6    | 14  |
| 451 | Immuntherapie von Hirntumoren. <i>Aktuelle Neurologie</i> , <b>2017</b> , 44, 400-408  |      |     |
| 450 | Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. <i>Acta Neuropathologica</i> , <b>2017</b> , 134, 905-922   | 14.3 | 9   |
| 449 | Meeting Update-World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 1457-1459  | 1    | 2   |
| 448 | Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1373-1385  | 21.7 | 518 |
| 447 | Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in -Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6846-6855   | 12.9 | 94  |
| 446 | Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells. <i>NeuroSignals</i> , <b>2017</b> , 25, 26-38  | 1.9  | 22  |
| 445 | Evidence-based management of adult patients with diffuse glioma - Authors' reply. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e430-e431  | 21.7 | 4   |
| 444 | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , <b>2017</b> , 390, 1645-1653  | 40   | 225 |
| 443 | Negative control of the HGF/c-MET pathway by TGF- $\beta$ a new look at the regulation of stemness in glioblastoma. <i>Cell Death and Disease</i> , <b>2017</b> , 8, 3210  | 9.8  | 23  |
| 442 | Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e709-e710  | 21.7 | 4   |
| 441 | Iterative analysis of cerebrovascular reactivity dynamic response by temporal decomposition. <i>Brain and Behavior</i> , <b>2017</b> , 7, e00705   | 3.4  | 28  |
| 440 | Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1954-1963   | 59.2 | 425 |
| 439 | Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , <b>2017</b> , 87, 189-198  | 7.5  | 25  |
| 438 | European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e330-e340   | 21.7 | 138 |
| 437 | Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109, 1-4  | 9.7  | 31  |
| 436 | cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. <i>Brain Pathology</i> , <b>2017</b> , 27, 851-852   | 6    | 36  |

|     |  |      |     |
|-----|--|------|-----|
| 435 | Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 12-21   | 1    | 65  |
| 434 | LTKB-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE  | 1    | 9   |
| 433 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 2306-2316                       | 27.4 | 875 |
| 432 | ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS COLLABORATIVE CONSORTIUM. <i>Neuro-Oncology</i> , <b>2017</b> , 19, vi5-vi6   | 1    | 78  |
| 431 | Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2038-2038  | 2.2  | 1   |
| 430 | Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. <i>Oncotarget</i> , <b>2017</b> , 8, 87124-87135  | 3.3  | 6   |
| 429 | The value of 18F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2076-2076 | 2.2  |     |
| 428 | Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2057-2057  | 2.2  |     |
| 427 | Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 454-456   | 1    | 22  |
| 426 | Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. <i>Brain</i> , <b>2017</b> , 140, e17  | 11.2 |     |
| 425 | Gliomatosis cerebri: no evidence for a separate brain tumor entity. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 309-319  | 14.3 | 59  |
| 424 | Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3107-8   | 2.2  | 1   |
| 423 | Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. <i>Cancer</i> , <b>2016</b> , 122, 3740-3741   | 6.4  | 2   |
| 422 | DRES-13. EXTENDED TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi54-vi54   | 1    |     |
| 421 | An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery. <i>Journal of Visualized Experiments</i> , <b>2016</b> ,   | 1.6  | 2   |
| 420 | Immunotherapy of Brain Cancer. <i>Oncology Research and Treatment</i> , <b>2016</b> , 39, 326-34   | 2.8  | 11  |
| 419 | Glioblastoma in the elderly: making sense of the evidence. <i>Neuro-Oncology Practice</i> , <b>2016</b> , 3, 77-86   | 2.2  | 9   |
| 418 | Boswellic acid activity against glioblastoma stem-like cells. <i>Oncology Letters</i> , <b>2016</b> , 11, 4187-4192  | 2.6  | 8   |

|     |  |     |     |
|-----|--|-----|-----|
| 417 | Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. <i>Public Health Genomics</i> , <b>2016</b> , 19, 170-7  | 1.9 | 2   |
| 416 | Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 129, 165-71   | 4.8 | 24  |
| 415 | Limited role for transforming growth factor- $\beta$ pathway activation-mediated escape from VEGF inhibition in murine glioma models. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1610-1621  | 1   | 22  |
| 414 | Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 744-51                         | 1   | 46  |
| 413 | Interleukin-33 in human gliomas: Expression and prognostic significance. <i>Oncology Letters</i> , <b>2016</b> , 12, 445-452   | 2.6 | 23  |
| 412 | Therapeutic options in recurrent glioblastoma--An update. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 99, 389-408   | 7   | 130 |
| 411 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 731-9 <sup>2.2</sup> |     | 108 |
| 410 | Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1463-1475  | 5   | 31  |
| 409 | Glioblastoma. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2016</b> , 134, 381-97   | 3   | 160 |
| 408 | Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1242-52   | 1   | 48  |
| 407 | 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1021-7   | 1   | 51  |
| 406 | Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 549-56                               | 1   | 129 |
| 405 | Altered intraoperative cerebrovascular reactivity in brain areas of high-grade glioma recurrence. <i>Magnetic Resonance Imaging</i> , <b>2016</b> , 34, 803-808  | 3.3 | 16  |
| 404 | Predicting outcome of epilepsy after meningioma resection. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1002-10   | 1   | 37  |
| 403 | Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 401-7   | 1   | 41  |
| 402 | EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2001-2001                          | 2.2 | 34  |
| 401 | EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2042-2042  | 2.2 | 3   |
| 400 | Correlation of IDH mutation, 1p/19q co-deletion and 18FET-PET derived time-to-peak analysis as prognostic markers in glioma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2058-2058                                       | 2.2 | 1   |

|     |  |     |    |
|-----|--|-----|----|
| 399 | Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA2000-LBA2000  | 2.2 | 7  |
| 398 | A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA2000-LBA2000 | 2.2 | 26 |
| 397 | Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA2000-LBA2000  | 2.2 | 14 |
| 396 | Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 81995-82012  | 3.3 | 10 |
| 395 | Prognostic relevance of miRNA-155 methylation in anaplastic glioma. <i>Oncotarget</i> , <b>2016</b> , 7, 82028-82045   | 3.3 | 15 |
| 394 | Control of glioma cell migration and invasiveness by GDF-15. <i>Oncotarget</i> , <b>2016</b> , 7, 7732-46  | 3.3 | 31 |
| 393 | MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. <i>Oncotarget</i> , <b>2016</b> , 7, 12937-50   | 3.3 | 47 |
| 392 | Direct contact with perivascular tumor cells enhances integrin $\alpha 5 \beta 1$ signaling and migration of endothelial cells. <i>Oncotarget</i> , <b>2016</b> , 7, 43852-43867   | 3.3 | 18 |
| 391 | Novel cases of amyotrophic lateral sclerosis after treatment of cerebral arteriovenous malformations. <i>Swiss Medical Weekly</i> , <b>2016</b> , 146, w14361  | 3.1 | 3  |
| 390 | Intravenous vs. intra-arterial methotrexate-based chemotherapy regimens for newly diagnosed primary central nervous system lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e13505-e13505  | 2.2 |    |
| 389 | Current State of Immune-Based Therapies for Glioblastoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e132-9  | 7.1 | 8  |
| 388 | Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , <b>2016</b> , 7, 15018-32   | 3.3 | 49 |
| 387 | ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERS COLLABORATIVE CONSORTIUM. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi5-vi5   | 1   |    |
| 386 | ACTR-30. EORTC 1608: A PHASE 1B STUDY OF TG02, AN ORAL CYCLIN-DEPENDENT KINASE 9/5 INHIBITOR, IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA STRATIFIED BY MGMT PROMOTER METHYLATION STATUS. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi8-vi8  | 1   | 1  |
| 385 | BMET-18. DIAGNOSIS AND TREATMENT PATTERNS FOR PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS ACROSS EUROPE. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi30-vi30   | 1   |    |
| 384 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1529-1537   | 1   | 80 |
| 383 | Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. <i>Cancer</i> , <b>2016</b> , 122, 2206-15  | 6.4 | 52 |
| 382 | ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi1-vi2  | 1   | 1  |

|     |  |      |     |
|-----|--|------|-----|
| 381 | ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRVIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi17-vi18   | 1    | 29  |
| 380 | Corticosteroids compromise survival in glioblastoma. <i>Brain</i> , <b>2016</b> , 139, 1458-71   | 11.2 | 205 |
| 379 | Drei molekulare Marker für Hauptgruppen. <i>Info Onkologie</i> , <b>2016</b> , 19, 26-26   |      |     |
| 378 | Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1829-30  | 2.2  | 4   |
| 377 | Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1259-70  | 4    | 21  |
| 376 | Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4797-4806 | 12.9 | 77  |
| 375 | Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1199-208   | 1    | 398 |
| 374 | Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1538-1547   | 1    | 50  |
| 373 | Chemotherapy for intracranial ependymoma in adults. <i>BMC Cancer</i> , <b>2016</b> , 16, 287  | 4.8  | 17  |
| 372 | EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e383-917   | 9.17 | 414 |
| 371 | Immunological effects of chemotherapy and radiotherapy against brain tumors. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 1087-94  | 3.5  | 26  |
| 370 | HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , <b>2016</b> , 18, iii63.2-iii63  | 1    | 78  |
| 369 | The Role of Molecular Diagnostics in the Management of Patients with Gliomas. <i>Current Treatment Options in Oncology</i> , <b>2016</b> , 17, 51  | 5.4  | 25  |
| 368 | Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. <i>Genome Biology</i> , <b>2015</b> , 16, 16   | 18.3 | 65  |
| 367 | Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , <b>2015</b> , 130, 407-17   | 14.3 | 194 |
| 366 | Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e322-32  | 21.7 | 247 |
| 365 | Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. <i>Acta Neuropathologica</i> , <b>2015</b> , 129, 679-93             | 14.3 | 208 |
| 364 | Efficacy of Surgery and Further Treatment of Progressive Glioblastoma. <i>World Neurosurgery</i> , <b>2015</b> , 84, 301-7   | 2.1  | 31  |

|     |   |      |     |
|-----|---|------|-----|
| 363 | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2057-64                                      | 12.9 | 206 |
| 362 | Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. <i>Neurology</i> , <b>2015</b> , 84, 1242-8  | 6.5  | 72  |
| 361 | Immunosuppressive mechanisms in glioblastoma. <i>Neuro-Oncology</i> , <b>2015</b> , 17 Suppl 7, vii9-vii14  | 1    | 195 |
| 360 | Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , <i>The</i> , <b>2015</b> , 16, e534-e542  | 21.7 | 425 |
| 359 | Neurology--the next 10 years. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 658-64  | 15   | 6   |
| 358 | Malignant optic glioma - the spectrum of disease in a case series. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2015</b> , 253, 1187-94  | 3.8  | 25  |
| 357 | Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 1188-98   | 1    | 224 |
| 356 | New insights into acquired temozolomide resistance in glioblastoma?. <i>Brain</i> , <b>2015</b> , 138, 3468-70  | 11.2 | 5   |
| 355 | Corticosteroid use in neuro-oncology: an update. <i>Neuro-Oncology Practice</i> , <b>2015</b> , 2, 6-12   | 2.2  | 32  |
| 354 | ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , <b>2015</b> , 129, 133-46 | 14.3 | 313 |
| 353 | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 1064-75  | 1    | 356 |
| 352 | ATPS-73BIOLOGICAL ACTIVITY OF TUMOR-TREATING FIELDS (TTFIELDS) IN GLIOMA MODELS IN A PRECLINICAL SETTING. <i>Neuro-Oncology</i> , <b>2015</b> , 17, v34.3-v34   | 1    | 10  |
| 351 | Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 2132-45  | 7.5  | 60  |
| 350 | Glioma. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15017  | 51.1 | 368 |
| 349 | Computer-assisted quantification of motile and invasive capabilities of cancer cells. <i>Scientific Reports</i> , <b>2015</b> , 5, 15338  | 4.9  | 13  |
| 348 | Was sind niedriger-gradige Gliome?. <i>InFo Neurologie &amp; Psychiatrie</i> , <b>2015</b> , 17, 35-35  | 0    |     |
| 347 | Drei molekulare Marker für Hauptgruppen. <i>InFo Neurologie &amp; Psychiatrie</i> , <b>2015</b> , 17, 32-32   | 0    |     |
| 346 | Management of diffusely infiltrating glioma in the elderly. <i>Current Opinion in Oncology</i> , <b>2015</b> , 27, 502-9  | 4.2  | 8   |



|     |  |     |     |
|-----|--|-----|-----|
| 345 | Immunotherapy for glioblastoma: concepts and challenges. <i>Current Opinion in Neurology</i> , <b>2015</b> , 28, 639-46  | 46  | 22  |
| 344 | Interferon- $\gamma$ Modulates the Innate Immune Response against Glioblastoma Initiating Cells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139603  | 3-7 | 9   |
| 343 | Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma? <b>2015</b> , 34, 313-21  |     | 26  |
| 342 | Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 1016-21  | 1   | 36  |
| 341 | Brain Tumor Imaging. <i>Medical Radiology</i> , <b>2015</b> , 1-9  | 0.2 | 1   |
| 340 | ATNT-10 DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2015</b> , 17, v12.2-v12   | 1   | 1   |
| 339 | Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 1007-15 <sup>1</sup> |     | 34  |
| 338 | 136 Complete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial. <i>Neurosurgery</i> , <b>2015</b> , 62, 209                            | 3-2 | 6   |
| 337 | Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 382-90   | 7-5 | 26  |
| 336 | Differential regulation of TGF- $\beta$ -induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 254-65  | 1   | 52  |
| 335 | Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. <i>Neurology</i> , <b>2015</b> , 84, 710-9  | 6-5 | 112 |
| 334 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2001-2001                    | 2-2 | 7   |
| 333 | Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2007-2007  | 2-2 | 1   |
| 332 | Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2015-2015                                    | 2-2 | 22  |
| 331 | Long-term survival in patients with primary CNS lymphoma: Results from the G-PCNSL-SG1 trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2032-2032   | 2-2 | 3   |
| 330 | Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e13025-e13025   | 2-2 | 1   |
| 329 | Transforming growth factor- $\beta$ pathway activity in glioblastoma. <i>Oncotarget</i> , <b>2015</b> , 6, 5963-77   | 3-3 | 68  |
| 328 | Modulation of cerebral endothelial cell function by TGF- $\beta$ in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. <i>Oncotarget</i> , <b>2015</b> , 6, 22480-95                           | 3-3 | 42  |

|     |  |      |     |
|-----|--|------|-----|
| 327 | Management of neoplastic meningitis. <i>Chinese Clinical Oncology</i> , <b>2015</b> , 4, 26  | 2.3  | 20  |
| 326 | Hirntumoren <b>2015</b> , 609-619  |      |     |
| 325 | Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2041-2041   | 2.2  |     |
| 324 | Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma. <i>Genes Chromosomes and Cancer</i> , <b>2014</b> , 53, 589-605   | 5    | 17  |
| 323 | Thymosin $\beta$ 4 gene silencing decreases stemness and invasiveness in glioblastoma. <i>Brain</i> , <b>2014</b> , 137, 433-441   | 4.2  | 29  |
| 322 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 117, 141-5   | 4.8  | 45  |
| 321 | Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma. <i>Nature Reviews Neurology</i> , <b>2014</b> , 10, 68-70   | 15   | 17  |
| 320 | Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1822-31  | 7.5  | 89  |
| 319 | Treatment of primary CNS lymphoma. <i>Current Treatment Options in Neurology</i> , <b>2014</b> , 16, 277   | 4.4  | 15  |
| 318 | The legend of cytomegalovirus and glioblastoma lives on. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 166   | 1    | 8   |
| 317 | Immunological challenges for peptide-based immunotherapy in glioblastoma. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 248-58   | 14.4 | 38  |
| 316 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1100-8 | 21.7 | 629 |
| 315 | EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology</i> , <b>2014</b> , 15, e395-403   | 21.7 | 498 |
| 314 | 3-Nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 1522-30  | 7.3  | 19  |
| 313 | Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. <i>Journal of Neurochemistry</i> , <b>2014</b> , 131, 251-64  | 6    | 29  |
| 312 | Interferon- $\gamma$ induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 948-61   | 6.1  | 40  |
| 311 | Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 118, 321-328  | 4.8  | 19  |
| 310 | A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 382-91  | 1    | 39  |

|     |  |      |     |
|-----|--|------|-----|
| 309 | Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 561-71   | 14.3 | 148 |
| 308 | Genetic variants of homocysteine metabolism and multiple sclerosis: a case-control study. <i>Neuroscience Letters</i> , <b>2014</b> , 562, 75-8  | 3.3  | 10  |
| 307 | MGMT testing--the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , <b>2014</b> , 10, 372-85  | 15   | 316 |
| 306 | ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. <i>International Journal of Oncology</i> , <b>2014</b> , 44, 1843-52  | 4.4  | 174 |
| 305 | MicroRNAs in Primary Brain Tumors: Functional Impact and Potential Use for Diagnostic Purposes <b>2014</b> , 25-38   |      |     |
| 304 | Reciprocal modulation of Aβ2 aggregation by copper and homocysteine. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 237   | 5.3  | 5   |
| 303 | Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460]. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 120, 665-6    | 4.8  | 15  |
| 302 | Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. <i>Acta Oncologica</i> , <b>2014</b> , 53, 1436-40  | 3.2  | 8   |
| 301 | Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 584-8   | 1    | 50  |
| 300 | The management of lomustine overdose in malignant glioma patients. <i>Neuro-Oncology Practice</i> , <b>2014</b> , 1, 178-183   | 2.2  | 6   |
| 299 | Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. <i>Chemotherapy</i> , <b>2014</b> , 60, 375-8   | 3.2  | 9   |
| 298 | Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1630-8   | 1.8  | 59  |
| 297 | Does cilengitide deserve another chance?-Authors' reply. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e585-e586   | 21.7 | 10  |
| 296 | Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. <i>Neuro-Oncology</i> , <b>2014</b> , 16 Suppl 8, viii14-9   | 1    | 42  |
| 295 | Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 2437-47 | 7.5  | 73  |
| 294 | The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1035-6   | 1    | 8   |
| 293 | How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2014</b> , 73, 1062-77   | 3.1  | 14  |
| 292 | mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 409-14   | 11.5 | 126 |

|     |   |      |     |
|-----|---|------|-----|
| 291 | Posttranslationally Modified Proteins in the Central Nervous System (CNS) Are the Dominant Antigenic Target/Stimulus of the B-Cell Receptor (BCR) in Primary CNS Lymphomas (PCNSL) Providing Strong Evidence for the Role of Chronic Autoantigenic Stimulation As an Early Step in the Pathogenesis of Aggressive B-Cell Lymphomas. <i>Blood</i> , <b>2014</b> , 124, 142-142 | 2.2  | 1   |
| 290 | Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2014-2014   | 2.2  | 9   |
| 289 | MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2015-2015   | 2.2  | 4   |
| 288 | Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2017-2017   | 2.2  | 3   |
| 287 | G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8527-8527   | 2.2  | 2   |
| 286 | Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. <i>PLoS ONE</i> , <b>2014</b> , 9, e94921   | 3.7  | 10  |
| 285 | MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. <i>Oncotarget</i> , <b>2014</b> , 5, 7651-62  | 3.3  | 66  |
| 284 | Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. <i>Current Treatment Options in Oncology</i> , <b>2013</b> , 14, 505-13   | 5.4  | 16  |
| 283 | Molecular neuro-oncology in clinical practice: a new horizon. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, e370-9  | 21.7 | 149 |
| 282 | ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 443-51  | 14.3 | 239 |
| 281 | Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 907-15   | 14.3 | 211 |
| 280 | Invasion patterns in brain metastases of solid cancers. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 1664-72   | 1    | 143 |
| 279 | EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. <i>Cancer Cell</i> , <b>2013</b> , 24, 438-49   | 24.3 | 181 |
| 278 | Optimal management of elderly patients with glioblastoma. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 350-7   | 14.4 | 108 |
| 277 | Integrin control of the transforming growth factor- $\beta$ pathway in glioblastoma. <i>Brain</i> , <b>2013</b> , 136, 564-76   | 11.2 | 76  |
| 276 | Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. <i>Neurology</i> , <b>2013</b> , 81, 1515-22   | 6.5  | 160 |
| 275 | Targeting apoptosis pathways in glioblastoma. <i>Cancer Letters</i> , <b>2013</b> , 332, 335-45   | 9.9  | 49  |
| 274 | Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 21-37   | 14.3 | 13  |

|     |   |      |     |
|-----|---|------|-----|
| 273 | Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 1017-26  | 1    | 65  |
| 272 | End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 1251-6   | 1    | 27  |
| 271 | Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 2803-11   | 16.6 | 147 |
| 270 | Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2013</b> , 72, 933-41   | 3.1  | 7   |
| 269 | Malignant astrocytoma in elderly patients: where do we stand?. <i>Current Opinion in Neurology</i> , <b>2013</b> , 26, 693-700  | 7.1  | 7   |
| 268 | Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5146-57  | 12.9 | 120 |
| 267 | Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. <i>European Neurology</i> , <b>2013</b> , 69, 95-101   | 2.1  | 20  |
| 266 | α-Integrin isoform expression in primary human tumors and brain metastases. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 2362-71   | 7.5  | 78  |
| 265 | Tumor-associated edema in brain cancer patients: pathogenesis and management. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 1319-25  | 3.5  | 32  |
| 264 | Standards of care for treatment of recurrent glioblastoma--are we there yet?. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 4-27  | 1    | 432 |
| 263 | Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. <i>PLoS ONE</i> , <b>2013</b> , 8, e63527   | 3.7  | 12  |
| 262 | Prognostic value of 18FET positron emission tomography (18FET-PET) for the clinical course in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2045-2045  | 2.2  | 1   |
| 261 | Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2059-2059  | 2.2  | 1   |
| 260 | Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2092-2092  | 2.2  | 2   |
| 259 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA2009-LBA2009 | 2.2  | 24  |
| 258 | Role of Integrins in Angiogenesis <b>2013</b> , 79-91   |      | 1   |
| 257 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA2009-LBA2009  | 2.2  | 2   |
| 256 | Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2027-2027  | 2.2  |     |

|     |   |      |     |
|-----|---|------|-----|
| 255 | Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS2103-TPS2103   | 2.2  |     |
| 254 | Effect of silencing thymosin beta 4 gene expression on stemness and invasiveness in glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2081-2081  | 2.2  |     |
| 253 | Induction of atypical anoikis in glioma cells through inhibition of integrin functions.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2079-2079  | 2.2  |     |
| 252 | Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. <i>Acta Neurochirurgica</i> , <b>2012</b> , 154, 229-35; discussion 235  | 3    | 40  |
| 251 | Immunology of brain tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 104, 45-51   | 3    | 14  |
| 250 | Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e196-204  | 21.7 | 43  |
| 249 | Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 707-15  | 21.7 | 792 |
| 248 | Pathogenesis and management of primary CNS lymphoma. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 623-33  | 3.5  | 18  |
| 247 | Costimulatory protein 41gB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 105-17  | 12.9 | 91  |
| 246 | Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. <i>Journal of Neurochemistry</i> , <b>2012</b> , 122, 444-55  | 6    | 107 |
| 245 | MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. <i>Acta Neuropathologica</i> , <b>2012</b> , 124, 547-60 | 14.3 | 213 |
| 244 | Epilepsy meets cancer: when, why, and what to do about it?. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e375-82   | 21.7 | 107 |
| 243 | Elderly people with glioblastoma [Authors' reply]. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e329   | 21.7 | 1   |
| 242 | HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. <i>Journal of Neuroimmunology</i> , <b>2012</b> , 250, 27-34   | 3.5  | 33  |
| 241 | Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 872-80  | 2.6  | 6   |
| 240 | 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 766-8  | 7.5  | 70  |
| 239 | Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 1342-50  | 7.5  | 180 |
| 238 | Clinical implications of molecular neuropathology and biomarkers for malignant glioma. <i>Current Neurology and Neuroscience Reports</i> , <b>2012</b> , 12, 302-7  | 6.6  | 20  |

|     |  |      |      |
|-----|--|------|------|
| 237 | Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. <i>Acta Neuropathologica</i> , <b>2012</b> , 123, 841-52 | 14.3 | 68   |
| 236 | Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. <i>Neuro-Oncology</i> , <b>2012</b> , 14, 471-81   | 1    | 7    |
| 235 | Drug-related problems and factors influencing acceptance of clinical pharmacologists' alerts in a large cohort of neurology inpatients. <i>Swiss Medical Weekly</i> , <b>2012</b> , 142, w13615  | 3.1  | 13   |
| 234 | Individualized targeted therapy for glioblastoma: fact or fiction?. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2012</b> , 18, 40-4   | 2.2  | 57   |
| 233 | Shaping the glioma immune microenvironment through tryptophan metabolism. <i>CNS Oncology</i> , <b>2012</b> , 1, 99-106  | 4    | 21   |
| 232 | Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. <i>Neuro-Oncology</i> , <b>2012</b> , 14 Suppl 4, iv100-8   | 1    | 120  |
| 231 | Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 605-17  | 5.9  | 19   |
| 230 | Surgery for primary CNS lymphoma? Challenging a paradigm. <i>Neuro-Oncology</i> , <b>2012</b> , 14, 1481-4   | 1    | 149  |
| 229 | Epidermal growth factor receptor: a re-emerging target in glioblastoma. <i>Current Opinion in Neurology</i> , <b>2012</b> , 25, 774-9  | 7.1  | 66   |
| 228 | MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2000-2000  | 2.2  | 1    |
| 227 | Effect of the integrin inhibitor cilengitide on TGF-beta signaling.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2055-2055   | 2.2  | 6    |
| 226 | Bevacizumab failure in glioblastomas.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2067-2067   | 2.2  | 2    |
| 225 | Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS2105-TPS2105  | 2.2  | 0    |
| 224 | Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. <i>PLoS ONE</i> , <b>2012</b> , 7, e33449  | 3.7  | 96   |
| 223 | Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2007-2007  | 2.2  |      |
| 222 | Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , <b>2011</b> , 50, 630-5   | 3.2  | 34   |
| 221 | Cilengitide: an RGD pentapeptide $\alpha$ and $\beta$ integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , <b>2011</b> , 7, 339-54  | 3.6  | 82   |
| 220 | An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. <i>Nature</i> , <b>2011</b> , 478, 197-203   | 50.4 | 1185 |

|     |   |      |     |
|-----|---|------|-----|
| 219 | Whole-brain radiotherapy in primary CNS lymphoma [Authors' reply]. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 119-120  | 21.7 | 5   |
| 218 | Geriatric neuro-oncology: from mythology to biology. <i>Current Opinion in Neurology</i> , <b>2011</b> , 24, 599-604  | 7.1  | 20  |
| 217 | A specific miRNA signature in the peripheral blood of glioblastoma patients. <i>Journal of Neurochemistry</i> , <b>2011</b> , 118, 449-57   | 6    | 141 |
| 216 | CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. <i>EMBO Journal</i> , <b>2011</b> , 30, 4309-22   | 13   | 123 |
| 215 | Nanomania [ante portas of neurooncology?]. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 104, 613-614  | 4.8  | 0   |
| 214 | Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 104, 801-9   | 4.8  | 10  |
| 213 | Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. <i>Acta Neuropathologica</i> , <b>2011</b> , 122, 353-65  | 14.3 | 58  |
| 212 | Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. <i>Current Neurology and Neuroscience Reports</i> , <b>2011</b> , 11, 305-12   | 6.6  | 43  |
| 211 | Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System). <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 930-8 | 2.6  | 14  |
| 210 | Bevacizumab does not increase the risk of remote relapse in malignant glioma. <i>Annals of Neurology</i> , <b>2011</b> , 69, 586-92   | 9.4  | 62  |
| 209 | Current concepts and management of glioblastoma. <i>Annals of Neurology</i> , <b>2011</b> , 70, 9-21  | 9.4  | 319 |
| 208 | NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. <i>Annals of Neurology</i> , <b>2011</b> , 70, 445-53  | 9.4  | 49  |
| 207 | Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. <i>Glia</i> , <b>2011</b> , 59, 1200-4  | 9    | 36  |
| 206 | Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 659-70   | 7.5  | 213 |
| 205 | Pathway inhibition: emerging molecular targets for treating glioblastoma. <i>Neuro-Oncology</i> , <b>2011</b> , 13, 566-79  | 1    | 104 |
| 204 | Molecular markers in low-grade gliomas: predictive or prognostic?. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4588-99  | 12.9 | 145 |
| 203 | APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. <i>Neuro-Oncology</i> , <b>2011</b> , 13, 155-64   | 1    | 37  |
| 202 | Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). <i>Neuro-Oncology</i> , <b>2011</b> , 13, 559-60; author reply 561-2  | 1    | 11  |



|     |  |      |     |
|-----|--|------|-----|
| 201 | The role of integrins in glioma biology and anti-glioma therapies. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 2402-10  | 3.3  | 33  |
| 200 | Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma?. <i>Neuro-Oncology</i> , <b>2011</b> , 13, 365-6  | 1    | 7   |
| 199 | Novel diagnostic and therapeutic approaches to malignant glioma. <i>Swiss Medical Weekly</i> , <b>2011</b> , 141, w1332-10   | 3.1  | 39  |
| 198 | Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i> , <b>2010</b> , 12, 894-907  | 1    | 14  |
| 197 | Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1168-74  | 2.2  | 367 |
| 196 | GDF-15 contributes to proliferation and immune escape of malignant gliomas. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3851-9   | 12.9 | 105 |
| 195 | Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2712-8 | 2.2  | 338 |
| 194 | Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e696-e697   | 2.2  |     |
| 193 | Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). <i>Stem Cells and Development</i> , <b>2010</b> , 19, 657-68  | 4.4  | 43  |
| 192 | Bevacizumab and recurrent malignant gliomas: a European perspective. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e188-9; author reply e190-2   | 2.2  | 92  |
| 191 | Angiogenesis in glioblastoma: just another moving target?. <i>Brain</i> , <b>2010</b> , 133, 955-6   | 11.2 | 8   |
| 190 | Glioma tropism of lentivirally transduced hematopoietic progenitor cells. <i>International Journal of Oncology</i> , <b>2010</b> , 36, 1409-17   | 4.4  | 8   |
| 189 | Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. <i>Future Oncology</i> , <b>2010</b> , 6, 1407-14  | 3.6  | 20  |
| 188 | High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. <i>Lancet Oncology</i> , <b>2010</b> , 11, 1036-47  | 21.7 | 417 |
| 187 | Steroids in neurooncology: actions, indications, side-effects. <i>Current Opinion in Neurology</i> , <b>2010</b> , 23, 597-602   | 6.0  | 66  |
| 186 | Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. <i>Journal of Neurosurgery</i> , <b>2010</b> , 113, 280-5   | 3.2  | 26  |
| 185 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. <i>Nature Reviews Neurology</i> , <b>2010</b> , 6, 39-51   | 15   | 538 |
| 184 | Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 77, 670-6  | 4    | 40  |

|     |   |      |     |
|-----|---|------|-----|
| 183 | Molecular diagnostics of gliomas: the clinical perspective. <i>Acta Neuropathologica</i> , <b>2010</b> , 120, 585-92  | 14.3 | 96  |
| 182 | Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <i>Acta Neuropathologica</i> , <b>2010</b> , 120, 707-18 | 14.3 | 596 |
| 181 | Targeting integrins in malignant glioma. <i>Targeted Oncology</i> , <b>2010</b> , 5, 175-81   | 5    | 73  |
| 180 | Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 96, 393-402  | 4.8  | 111 |
| 179 | Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica?. <i>Pain</i> , <b>2010</b> , 149, 470-475  | 8    | 20  |
| 178 | Systemic Relapses In Primary CNS Lymphoma (PCNSL) - Unexpected Clonal Diversity. <i>Blood</i> , <b>2010</b> , 116, 3125-3125  | 2.2  | 1   |
| 177 | SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6609-18  | 12.9 | 17  |
| 176 | Movement disorders reveal Creutzfeldt-Jakob disease. <i>Nature Reviews Neurology</i> , <b>2009</b> , 5, 185-6   | 15   | 3   |
| 175 | Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. <i>Neuro-Oncology</i> , <b>2009</b> , 11, 747-56   | 1    | 68  |
| 174 | New (alternative) temozolomide regimens for the treatment of glioma. <i>Neuro-Oncology</i> , <b>2009</b> , 11, 69-79  | 1    | 125 |
| 173 | Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 530-40  | 7.5  | 41  |
| 172 | Ceramide metabolism determines glioma cell resistance to chemotherapy. <i>Journal of Cellular Physiology</i> , <b>2009</b> , 221, 688-95  | 7    | 18  |
| 171 | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. <i>Acta Neuropathologica</i> , <b>2009</b> , 118, 469-74  | 14.3 | 874 |
| 170 | Rechallenge with temozolomide in patients with recurrent gliomas. <i>Journal of Neurology</i> , <b>2009</b> , 256, 734-41   | 5.5  | 80  |
| 169 | ACNU-based chemotherapy for recurrent glioma in the temozolomide era. <i>Journal of Neuro-Oncology</i> , <b>2009</b> , 92, 45-8   | 4.8  | 36  |
| 168 | Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. <i>Stem Cells</i> , <b>2009</b> , 27, 909-19  | 5.8  | 224 |
| 167 | Will integrin inhibitors have proangiogenic effects in the clinic?. <i>Nature Medicine</i> , <b>2009</b> , 15, 726; author reply 727  | 50.5 | 25  |
| 166 | Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. <i>Brain</i> , <b>2009</b> , 132, 1509-22  | 11.2 | 36  |

|     |   |      |      |
|-----|---|------|------|
| 165 | NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5874-80 <sup>2,2</sup>                      | 2.2  | 625  |
| 164 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 459-66 | 21.7 | 5111 |
| 163 | Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1257-61   | 2.2  | 108  |
| 162 | Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5743-50              | 2.2  | 464  |
| 161 | Classification and management of anaplastic gliomas. <i>Current Opinion in Neurology</i> , <b>2009</b> , 22, 650-6  | 7.1  | 10   |
| 160 | Adjuvant therapy. <i>Recent Results in Cancer Research</i> , <b>2009</b> , 171, 141-53  | 1.5  | 2    |
| 159 | Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. <i>Cancer Letters</i> , <b>2008</b> , 270, 30-9   | 9.9  | 26   |
| 158 | Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. <i>Journal of Neurochemistry</i> , <b>2008</b> , 106, 2436-48   | 6    | 24   |
| 157 | Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 29-38  | 21.7 | 407  |
| 156 | Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4189-99                   | 2.2  | 625  |
| 155 | Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. <i>Journal of Immunology</i> , <b>2008</b> , 180, 7338-48   | 5.3  | 119  |
| 154 | VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. <i>Brain</i> , <b>2008</b> , 131, 2579-95  | 11.2 | 18   |
| 153 | A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , <b>2008</b> , 10, 1019-24  | 1    | 63   |
| 152 | Anticoagulation for radiation-induced neurotoxicity revisited. <i>Journal of Neuro-Oncology</i> , <b>2008</b> , 90, 357-62 <sup>8</sup>   | 16   |      |
| 151 | Molekular definierte Chemotherapien und zielgerichtete Therapien bei malignen Gliomen. <i>Onkopipeline</i> , <b>2008</b> , 1, 11-16   |      |      |
| 150 | Mechanisms of chemoresistance to alkylating agents in malignant glioma. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2900-8  | 12.9 | 273  |
| 149 | Modulating TGF- $\beta$ Receptor Signaling: A Novel Approach of Cancer Therapy <b>2008</b> , 653-669  |      |      |
| 148 | Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. <i>International Journal of Oncology</i> , <b>2008</b> , 33, 759-65  | 1    | 15   |

|     |  |      |     |
|-----|--|------|-----|
| 147 | Synergistic antiglioma activity of radiotherapy and enzastaurin. <i>Annals of Neurology</i> , <b>2007</b> , 61, 153-61   | 9.4  | 67  |
| 146 | Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. <i>Journal of Neuroscience Research</i> , <b>2007</b> , 85, 1336-46       | 4.4  | 103 |
| 145 | Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. <i>Journal of Neuroimmunology</i> , <b>2007</b> , 189, 50-8  | 3.5  | 46  |
| 144 | Long-term survival with glioblastoma multiforme. <i>Brain</i> , <b>2007</b> , 130, 2596-606  | 11.2 | 624 |
| 143 | Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. <i>Neuro-Oncology</i> , <b>2007</b> , 9, 259-70  | 1    | 72  |
| 142 | Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6933-7   | 12.9 | 119 |
| 141 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3357-61  | 2.2  | 208 |
| 140 | Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. <i>Cellular Physiology and Biochemistry</i> , <b>2007</b> , 20, 23-34   | 3.9  | 19  |
| 139 | Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. <i>Cancer Research</i> , <b>2007</b> , 67, 3540-4   | 10.1 | 77  |
| 138 | Pirfenidone inhibits TGF-beta expression in malignant glioma cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2007</b> , 354, 542-7  | 3.4  | 47  |
| 137 | Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 1728-35 | 7.5  | 33  |
| 136 | Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression. <i>Cancer Research</i> , <b>2006</b> , 66, 3852-8  | 10.1 | 21  |
| 135 | Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. <i>Brain</i> , <b>2006</b> , 129, 2426-35                               | 11.2 | 107 |
| 134 | TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. <i>Brain</i> , <b>2006</b> , 129, 2416-25   | 11.2 | 170 |
| 133 | Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. <i>Current Pharmaceutical Design</i> , <b>2006</b> , 12, 341-9   | 3.3  | 113 |
| 132 | Changing paradigms--an update on the multidisciplinary management of malignant glioma. <i>Oncologist</i> , <b>2006</b> , 11, 165-80  | 5.7  | 316 |
| 131 | Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4412-7                                   | 2.2  | 131 |
| 130 | Apoptosis Pathways and Chemotherapy <b>2006</b> , 141-154  |      |     |

|     |   |      |       |
|-----|---|------|-------|
| 129 | Regulation of pulmonary <i>Pseudomonas aeruginosa</i> infection by the transcriptional repressor Gfi1. <i>Cellular Microbiology</i> , <b>2006</b> , 8, 1096-105   | 3.9  | 15    |
| 128 | O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. <i>Journal of Neurochemistry</i> , <b>2006</b> , 96, 766-76   | 6    | 253   |
| 127 | Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. <i>Brain</i> , <b>2005</b> , 128, 2200-11   | 11.2 | 73    |
| 126 | HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2005</b> , 64, 523-8  | 3.1  | 110   |
| 125 | MGMT gene silencing and benefit from temozolomide in glioblastoma. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 997-1003   | 59.2 | 5267  |
| 124 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 987-96  | 59.2 | 13703 |
| 123 | Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 328, 125-9  | 3.4  | 53    |
| 122 | Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death. <i>Journal of Neurochemistry</i> , <b>2005</b> , 92, 1340-9   | 6    | 6     |
| 121 | Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. <i>Journal of Neurochemistry</i> , <b>2005</b> , 93, 992-9  | 6    | 102   |
| 120 | Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. <i>Journal of Neuroimmunology</i> , <b>2005</b> , 162, 28-42  | 3.5  | 25    |
| 119 | Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. <i>International Journal of Cancer</i> , <b>2005</b> , 117, 1060-4        | 7.5  | 15    |
| 118 | Temozolomide: a milestone in the pharmacotherapy of brain tumors. <i>Future Oncology</i> , <b>2005</b> , 1, 747-54  | 3.6  | 27    |
| 117 | Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?. <i>Oncology Research and Treatment</i> , <b>2005</b> , 28, 391-6  | 2.8  | 47    |
| 116 | FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 6765-74                       | 6.6  | 47    |
| 115 | How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4235-6; author reply 4236  | 2.2  | 43    |
| 114 | RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. <i>Cancer Research</i> , <b>2004</b> , 64, 7596-603 | 10.1 | 251   |
| 113 | Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. <i>Cancer Research</i> , <b>2004</b> , 64, 1575-8   | 10.1 | 64    |
| 112 | SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. <i>Cancer Research</i> , <b>2004</b> , 64, 7954-61       | 10.1 | 347   |

|     |  |      |     |
|-----|--|------|-----|
| 111 | Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. <i>Journal of Neurochemistry</i> , <b>2004</b> , 91, 1067-74   | 6    | 51  |
| 110 | BCL-2-induced glioma cell invasiveness depends on furin-like proteases. <i>Journal of Neurochemistry</i> , <b>2004</b> , 91, 1275-83   | 6    | 34  |
| 109 | Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. <i>Cancer Gene Therapy</i> , <b>2004</b> , 11, 721-32  | 5.4  | 69  |
| 108 | MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model. <i>Journal of Neuro-Oncology</i> , <b>2004</b> , 66, 147-54   | 4.8  | 11  |
| 107 | Apoptosis in gliomas: molecular mechanisms and therapeutic implications. <i>Journal of Neuro-Oncology</i> , <b>2004</b> , 70, 245-54   | 4.8  | 74  |
| 106 | Leptomeningeal metastasis: survival and prognostic factors in 155 patients. <i>Journal of the Neurological Sciences</i> , <b>2004</b> , 223, 167-78  | 3.2  | 126 |
| 105 | Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 321, 524-30          | 3.4  | 52  |
| 104 | P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. <i>Brain Pathology</i> , <b>2003</b> , 13, 482-94  | 6    | 37  |
| 103 | Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 3276-84         | 2.2  | 121 |
| 102 | Characterization of daunorubicin-induced apoptosis in retinal pigment epithelial cells: modulation by CD95L. <i>Investigative Ophthalmology and Visual Science</i> , <b>2003</b> , 44, 2851-7  |      | 5   |
| 101 | Radiochemotherapy of malignant glioma in adults. Clinical experiences. <i>Strahlentherapie Und Onkologie</i> , <b>2003</b> , 179, 219-32   | 4.3  | 45  |
| 100 | PTEN methylation and expression in glioblastomas. <i>Acta Neuropathologica</i> , <b>2003</b> , 106, 479-85   | 14.3 | 102 |
| 99  | A prospective trial of mechanical physiotherapy for lumbar disk prolapse. <i>Journal of Neurology</i> , <b>2003</b> , 250, 746-9   | 5.5  | 16  |
| 98  | Involvement of protein kinase Cdelta and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). <i>Biochemical Pharmacology</i> , <b>2003</b> , 66, 1263-70 | 6    | 26  |
| 97  | Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. <i>Glia</i> , <b>2003</b> , 42, 379-89  | 9    | 81  |
| 96  | Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. <i>Annals of Neurology</i> , <b>2003</b> , 54, 388-92  | 9.4  | 180 |
| 95  | Adenoviral natural born killer gene therapy for malignant glioma. <i>Human Gene Therapy</i> , <b>2003</b> , 14, 1235-46  | 4.8  | 32  |
| 94  | Primary Tumors of the Central and Peripheral Nervous System <b>2003</b> , 827-863  |      | 5   |

|    |   |      |     |
|----|---|------|-----|
| 93 | Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. <i>Cancer Research</i> , <b>2003</b> , 63, 7462-7   | 10.1 | 272 |
| 92 | MICA/NKG2D-mediated immunogene therapy of experimental gliomas. <i>Cancer Research</i> , <b>2003</b> , 63, 8996-9006  | 10.1 | 137 |
| 91 | CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. <i>Brain Pathology</i> , <b>2002</b> , 12, 12-20  | 6    | 30  |
| 90 | Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. <i>Journal of Neuroscience</i> , <b>2002</b> , 22, 6401-7   | 6.6  | 252 |
| 89 | Apoptosis in gliomas, and its role in their current and future treatment. <i>Frontiers in Bioscience - Landmark</i> , <b>2002</b> , 7, e339-53  | 2.8  | 16  |
| 88 | Gliomatosis cerebri: molecular pathology and clinical course. <i>Annals of Neurology</i> , <b>2002</b> , 52, 390-9  | 9.4  | 66  |
| 87 | Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. <i>Cancer</i> , <b>2002</b> , 95, 1113-9  | 6.4  | 64  |
| 86 | Mechanisms of apoptosis in central nervous system tumors: application to theory. <i>Current Neurology and Neuroscience Reports</i> , <b>2002</b> , 2, 246-53  | 6.6  | 10  |
| 85 | Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. <i>Nature Medicine</i> , <b>2002</b> , 8, 808-15   | 50.5 | 698 |
| 84 | BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. <i>Journal of Neuro-Oncology</i> , <b>2002</b> , 56, 43-9  | 4.8  | 44  |
| 83 | Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study. <i>Journal of Neuro-Oncology</i> , <b>2002</b> , 59, 151-5  | 4.8  | 24  |
| 82 | A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. <i>Journal of Immunology</i> , <b>2002</b> , 168, 4772-80   | 5.3  | 277 |
| 81 | Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. <i>Cancer Research</i> , <b>2002</b> , 62, 1915-9   | 10.1 | 73  |
| 80 | Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. <i>Acta Neuropathologica</i> , <b>2001</b> , 101, 217-24   | 14.3 | 27  |
| 79 | Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment. <i>Cancer</i> , <b>2001</b> , 91, 130-5  | 6.4  | 43  |
| 78 | Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. <i>Cancer</i> , <b>2001</b> , 91, 423-7   | 6.4  | 29  |
| 77 | Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. <i>Microscopy Research and Technique</i> , <b>2001</b> , 52, 401-10   | 2.8  | 190 |
| 76 | N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta release and reduces migration and invasiveness of human malignant glioma cells. <i>International Journal of Cancer</i> , <b>2001</b> , 93, 53-61 | 7.5  | 74  |

|    |   |      |     |
|----|---|------|-----|
| 75 | Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. <i>Journal of Neuro-Oncology</i> , <b>2001</b> , 53, 177-85   | 4.8  | 195 |
| 74 | N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). <i>British Journal of Pharmacology</i> , <b>2001</b> , 134, 1279-84 | 8.6  | 18  |
| 73 | Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. <i>Oncogene</i> , <b>2001</b> , 20, 4757-67  | 9.2  | 49  |
| 72 | CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. <i>Oncogene</i> , <b>2001</b> , 20, 4128-37  | 9.2  | 98  |
| 71 | Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. <i>Journal of Immunology</i> , <b>2001</b> , 166, 7238-43  | 5.3  | 87  |
| 70 | Molecular determinants of glioma cell migration and invasion. <i>Journal of Neurosurgery</i> , <b>2001</b> , 94, 978-84   | 3.2  | 97  |
| 69 | Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 281, 322-7   | 3.4  | 24  |
| 68 | Diva/Boo is a negative regulator of cell death in human glioma cells. <i>FEBS Letters</i> , <b>2001</b> , 505, 23-6   | 3.8  | 15  |
| 67 | Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. <i>Journal of Neuroscience</i> , <b>2001</b> , 21, 3360-8  | 6.6  | 80  |
| 66 | Modulation of MDR/MRP by wild-type and mutant p53. <i>Journal of Clinical Investigation</i> , <b>2001</b> , 107, 643-6  | 15.9 | 33  |
| 65 | Death Ligand/Death Receptor-Mediated Apoptosis for Treatment of Brain Tumors <b>2001</b> , 327-344  |      |     |
| 64 | Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release. <i>Oncogene</i> , <b>2000</b> , 19, 2338-45  | 9.2  | 36  |
| 63 | Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. <i>Oncogene</i> , <b>2000</b> , 19, 4210-20   | 9.2  | 138 |
| 62 | Bag-1 and Bcl-2 gene transfer in malignant glioma: modulation of cell cycle regulation and apoptosis. <i>Brain Pathology</i> , <b>2000</b> , 10, 223-34   | 6    | 28  |
| 61 | Treosulfan chemotherapy for recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , <b>2000</b> , 49, 231-4  | 4.8  | 9   |
| 60 | Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 268, 607-11          | 3.4  | 120 |
| 59 | CD95/CD95 ligand interactions on epithelial cells in host defense to <i>Pseudomonas aeruginosa</i> . <i>Science</i> , <b>2000</b> , 290, 527-30   | 33.3 | 225 |
| 58 | Both the neuronal and inducible isoforms contribute to upregulation of retinal nitric oxide synthase activity by brain-derived neurotrophic factor. <i>Journal of Neuroscience</i> , <b>1999</b> , 19, 8517-27  | 6.6  | 96  |



|    |   |      |     |
|----|---|------|-----|
| 57 | p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis. <i>Cellular Physiology and Biochemistry</i> , <b>1999</b> , 9, 29-37                                       | 3.9  | 27  |
| 56 | Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. <i>Cell Death and Differentiation</i> , <b>1999</b> , 6, 370-6  | 12.7 | 109 |
| 55 | PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. <i>Oncogene</i> , <b>1999</b> , 18, 3936-43   | 9.2  | 97  |
| 54 | Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. <i>Oncogene</i> , <b>1999</b> , 18, 5044-53  | 9.2  | 44  |
| 53 | Glucocorticoid treatment of primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , <b>1999</b> , 43, 237-9  | 4.8  | 96  |
| 52 | Inhibition of experimental rat glioma growth by decorin gene transfer is associated with decreased microglial infiltration. <i>Journal of Neuroimmunology</i> , <b>1999</b> , 99, 13-8  | 3.5  | 20  |
| 51 | Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. <i>European Journal of Pharmacology</i> , <b>1999</b> , 365, 301-8   | 5.3  | 44  |
| 50 | Caspases as treatment targets in stroke and neurodegenerative diseases. <i>Annals of Neurology</i> , <b>1999</b> , 45, 421-9  | 9.4  | 288 |
| 49 | TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. <i>European Journal of Immunology</i> , <b>1999</b> , 29, 1032-40  | 6.1  | 29  |
| 48 | Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. <i>Experimental Cell Research</i> , <b>1999</b> , 253, 432-9 | 4.2  | 18  |
| 47 | Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. <i>Biochemical and Biophysical Research Communications</i> , <b>1999</b> , 259, 600-5                                  | 3.4  | 50  |
| 46 | Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. <i>Biochemical and Biophysical Research Communications</i> , <b>1999</b> , 265, 479-83    | 3.4  | 188 |
| 45 | Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. <i>Journal of Neuro-Oncology</i> , <b>1998</b> , 37, 191-8                                     | 4.8  | 12  |
| 44 | Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. <i>Journal of Neuro-Oncology</i> , <b>1998</b> , 39, 19-32   | 4.8  | 27  |
| 43 | New aspects of immunotherapy of leptomeningeal metastasis. <i>Journal of Neuro-Oncology</i> , <b>1998</b> , 38, 233-9   | 4.8  | 34  |
| 42 | Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?. <i>Journal of Neuro-Oncology</i> , <b>1998</b> , 40, 233-5   | 4.8  | 7   |
| 41 | Fas/CD95/Apo-I activates the acidic sphingomyelinase via caspases. <i>Cell Death and Differentiation</i> , <b>1998</b> , 5, 29-37   | 12.7 | 118 |
| 40 | Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. <i>Cell Death and Differentiation</i> , <b>1998</b> , 5, 847-57                                   | 12.7 | 89  |

|    |   |      |     |
|----|---|------|-----|
| 39 | Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. <i>Cell Death and Differentiation</i> , <b>1998</b> , 5, 894-900  | 12.7 | 50  |
| 38 | Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?. <i>Oncogene</i> , <b>1998</b> , 17, 1567-75  | 9.2  | 61  |
| 37 | Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer. <i>Oncogene</i> , <b>1998</b> , 17, 2323-32                       | 9.2  | 28  |
| 36 | Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , <b>1998</b> , 43, 116-20   | 9.4  | 66  |
| 35 | Factor V Leiden as a cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis?. <i>Annals of Neurology</i> , <b>1998</b> , 44, 426-7   | 9.4  | 4   |
| 34 | Retroviral BAX gene transfer fails to sensitize malignant glioma cells to CD95L-induced apoptosis and cancer chemotherapy. <i>International Journal of Cancer</i> , <b>1998</b> , 77, 645-8                                     | 7.5  | 10  |
| 33 | Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. <i>International Journal of Cancer</i> , <b>1998</b> , 79, 640-4  | 7.5  | 130 |
| 32 | Cellular stimulation via CD95 involves activation of phospho-inositide-3-kinase. <i>Pflugers Archiv European Journal of Physiology</i> , <b>1998</b> , 435, 546-54  | 4.6  | 10  |
| 31 | Predicting response to cancer chemotherapy: the role of p53. <i>Cell and Tissue Research</i> , <b>1998</b> , 292, 435-45  | 4.2  | 199 |
| 30 | CD95 ligand-induced apoptosis of human medulloblastoma cells. <i>Cancer Letters</i> , <b>1998</b> , 128, 121-6  | 9.9  | 10  |
| 29 | Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells. <i>Journal of Neuroimmunology</i> , <b>1998</b> , 87, 121-9  | 3.5  | 39  |
| 28 | APO2 ligand: a novel lethal weapon against malignant glioma?. <i>FEBS Letters</i> , <b>1998</b> , 427, 124-8  | 3.8  | 145 |
| 27 | CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression. <i>FEBS Letters</i> , <b>1998</b> , 432, 155-7   | 3.8  | 12  |
| 26 | BCL-2 promotes migration and invasiveness of human glioma cells. <i>FEBS Letters</i> , <b>1998</b> , 440, 419-24  | 3.8  | 79  |
| 25 | CD95 ligand: lethal weapon against malignant glioma?. <i>Brain Pathology</i> , <b>1998</b> , 8, 285-93  | 6    | 62  |
| 24 | Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. <i>Journal of Neurochemistry</i> , <b>1998</b> , 71, 88-94 | 6    | 161 |
| 23 | Potential of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2. <i>Biochemical Pharmacology</i> , <b>1998</b> , 55, 349-59                       | 6    | 26  |
| 22 | Synergy of CD95 ligand and teniposide: no role of cleavable complex formation and enhanced CD95 expression. <i>European Journal of Pharmacology</i> , <b>1998</b> , 341, 323-8  | 5.3  | 7   |

|    |   |     |     |
|----|---|-----|-----|
| 21 | BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. <i>Journal of the Neurological Sciences</i> , <b>1998</b> , 155, 68-75  | 3.2 | 67  |
| 20 | Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses <b>1998</b> , 79, 640  |     | 3   |
| 19 | Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone?. <i>Neurology</i> , <b>1997</b> , 48, 1704-9   | 6.5 | 81  |
| 18 | p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells. <i>Cellular Physiology and Biochemistry</i> , <b>1997</b> , 7, 304-311  | 3.9 | 6   |
| 17 | CD95-Dependent T-Cell Killing by Glioma Cells Expressing CD95 Ligand: More on Tumor Immune Escape, the CD95 Counterattack, and the Immune Privilege of the Brain. <i>Cellular Physiology and Biochemistry</i> , <b>1997</b> , 7, 282-288                  | 3.9 | 31  |
| 16 | Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. <i>Neurological Research</i> , <b>1997</b> , 19, 456-470   | 2.7 | 36  |
| 15 | Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. <i>FEBS Letters</i> , <b>1997</b> , 409, 17-23  | 3.8 | 31  |
| 14 | Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. <i>International Journal of Cancer</i> , <b>1997</b> , 73, 707-14 | 7.5 | 63  |
| 13 | Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species. <i>Journal of Neurochemistry</i> , <b>1997</b> , 69, 2075-86                            | 6   | 83  |
| 12 | Genetic Regulation and Therapeutic Modulation of Apoptosis in Human Malignant Glioma. <i>Cellular Physiology and Biochemistry</i> , <b>1996</b> , 6, 376-380  | 3.9 | 6   |
| 11 | Maturation-dependent modulation of apoptosis in cultured cerebellar granule neurons by cytokines and neurotrophins. <i>European Journal of Neuroscience</i> , <b>1996</b> , 8, 1994-2005  | 3.5 | 16  |
| 10 | T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. <i>Experimental Cell Research</i> , <b>1995</b> , 221, 395-403                         | 4.2 | 29  |
| 9  | Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. <i>European Journal of Immunology</i> , <b>1995</b> , 25, 2253-8   | 6.1 | 191 |
| 8  | Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 1293-300   | 6.1 | 103 |
| 7  | Tumor cell dissemination triggers an intrathecal immune response in neoplastic meningitis. <i>Cancer</i> , <b>1992</b> , 69, 1475-80  | 6.4 | 22  |
| 6  | Effective suppression of crescendo amaurosis fugax associated with anti-phospholipid antibodies by low dose aspirin. <i>Neuro-Ophthalmology</i> , <b>1991</b> , 11, 195-197   | 0.9 |     |
| 5  | Exploiting Apoptosis Pathways for Glioblastoma Therapy1033-1048   |     |     |
| 4  | Overall patient survival of glioblastoma associated to molecular markers: a pan-proteomic prospective study   |     | 2   |

- 3 Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment 2
- 2 Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion 2
- 1 The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen 1